Carla Grandori
Carla Grandori is Founder and President and Scientific Director at Cure First. She was VP head of Functional Clinical Modeling and Functional Genomics, Tempus AI Inc at Tempus AI and Chief Executive Officer at SEngine Precision Medicine. She was Research Member at Fred Hutch and Director at University of Washington. She is Leader, MYC Pathway, at the TCGA Pan-Cancer Analysis Project and Steering Committee Member at the Cancer Target Discovery & Development (CTD²) Network.
Recent coverage
Front-page news, podcasts and videos about Carla
SEngine Precision Medicine Raises $10M to Advance Paris Test for Personalized Cancer Drug Treatment
Seattle startup SEngine Precision Medicine raised $10 million to advance its Paris Test, which tailors cancer drug treatments by culturing patient tumor cells and testing drug responses. The test aims to provide personalized treatment options beyond traditional genomic tests and has been used by about 800 patients so far.
Fred Hutch spinout SEngine Precision Medicine raises $5.1M Series A to commercialize PARIS tumor‑testing platform
SEngine Precision Medicine raised $5.1 million to commercialize its PARIS platform, which grows patients’ tumor cells in the lab to test safety and effectiveness of over 200 drugs or drug combinations and help match cancer patients to therapies. The company also gathers data for drug discovery, has a joint venture with Atomwise, and completed a Series A led by the Bangarang Group.
SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board
SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.
By Carla
Carla Grandori announces Cure First’s PARIS® test helped guide effective treatment for a hard-to-treat sarcoma patient
Carla Grandori shares that a patient with a hard-to-treat sarcoma responded to treatment chosen using Cure First's PARIS® functional drug sensitivity test, which measures how a patient’s living tumor cells react to many drugs to help guide oncologists’ treatment decisions.
Organizations
See all 8-
Cure First Founder and President and Scientific Director 2025–present, Scientific Director 2014–present, President 2012–2025 · current
-
Tempus AI VP head of Functional Clinical Modeling and Functional Genomics, Tempus AI Inc 2023–2024 · past
-
SEngine Precision Medicine Chief Executive Officer 2015–2023 · past
Education
-
Massachusetts Institute of Technology Post-doctoral fellow, Cell/Cellular and Molecular Biology · 1989–1991
-
The Rockefeller University Doctor of Philosophy - PhD, Biochemistry and Molecular Biology · 1984–1990
-
Sapienza Università di Roma Doctor of Medicine - MD · 1976–1982
Online
Questions about Carla Grandori
Who is Carla Grandori?
Carla Grandori is Founder and President and Scientific Director at Cure First.
Which organizations is Carla Grandori associated with?
On Seattle Flow, Carla Grandori is listed with Cure First, Tempus AI, SEngine Precision Medicine and 5 more.
Where did Carla Grandori study?
Carla Grandori studied at Massachusetts Institute of Technology, The Rockefeller University and Sapienza Università di Roma.
Where is Carla Grandori based?
Carla Grandori is based in Seattle, Washington, United States.
Where can I find Carla Grandori online?
Carla Grandori is on LinkedIn.